Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
about
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?The endocannabinoid system, cannabinoids, and painMultiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disordersCannabinoids for pediatric epilepsy? Up in smoke or real science?Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disordersAre cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewCannabis and psychosis: NeurobiologyCannabinoids and Epilepsy.Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal MarketsGene-environment interactions in severe mental illness.The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.Medical use of cannabis. Cannabidiol: a new light for schizophrenia?The pharmacologic and clinical effects of medical cannabis.Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganizationFactors that lead to the use of crack cocaine in combination with marijuana in Brazil: a qualitative study.Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activationCannabinoids and Schizophrenia: Risks and Therapeutic PotentialCannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice.Pain, Cannabis Species, and Cannabis Use DisordersImpact of enzymatic and alkaline hydrolysis on CBD concentration in urine.Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?"Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report.The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.The association of cannabis use on inpatient psychiatric hospital outcomes.Is there a role for cannabidiol in psychiatry?Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex.Prescribing cannabis for harm reductionCannabis--a valuable drug that deserves better treatment.Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus.Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment.Cannabis, cannabinoids, and health.Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.Cannabinoid concentrations in Canada's regulated medical cannabis industry.
P2860
Q21129107-4F6352E1-DC06-476C-9BCA-F01FEEBB3BF4Q24601890-81F7A250-6058-456E-9FD3-77874168CE21Q24623179-F5D294CA-694F-4D1F-AC48-AD8FA0D76B06Q26770299-44703E52-EDF5-4BBF-A58A-B1511A3DA2D7Q26823267-3B2207D9-4296-4423-94AC-684BA4B92E05Q27005619-670E6FC9-7E7D-4C31-BD23-25860245DD44Q27024404-39FB2184-1322-4DC4-83ED-CF43895197B7Q27336451-C96E6F70-BB60-467D-AFFE-F467CA1CE39EQ33577070-D4D28C88-C82E-4994-BF3E-1D300500C049Q33647068-6C92BDC7-BD3C-44F7-B14E-62F23B843727Q33908169-6FE13DD0-6BE7-40E4-AD57-F853EEA66E58Q34304341-CD4E6FC3-0C43-40B0-A857-F06ED996E657Q34308885-C76C5E51-32D8-4450-8E03-65EEA2A25C0FQ34326515-79515FE2-781A-470F-B0ED-CC63676A0266Q34487906-F2FC70A6-756A-408D-B3C6-85596E3E0442Q34530386-D5C22071-38D8-487D-87F0-82095D7AA1F0Q34531537-09E757D8-FC9F-4259-9382-15AB854CD620Q34875298-E1EC90A0-C44F-475A-96B0-96F88F2816D6Q35216772-8C9D3ED2-1338-42F6-8CA0-18CD241699EEQ35713009-5A5FE90D-261E-4F3D-AEAC-BE316FB1AFD5Q35966006-9120A530-83D7-4DB2-AED2-F495BCA00906Q36157669-AEF4F8D1-2774-4A0E-8188-C7271D8508D1Q36785192-4C6BDE90-A5BC-4E11-8486-9545CA4C87BDQ36908804-6196E4C7-BF0B-4000-9C80-1A70DD1F2D83Q36987924-6AE60CE1-CDC6-4C59-B6FE-3559A920A3D9Q37274656-65DEF791-A04B-4B7D-BB61-4128BD8D698CQ37728621-7C9CC25A-8D3C-4604-AFEF-720EE0006613Q38012845-6AF71C43-161E-48FF-BBD6-211B0085CAEFQ38123778-51B6D2F8-344B-4BA4-A38D-0D579F4679C9Q38317405-C35F3BDA-80A5-4899-9B3C-873EC33CEF97Q38671126-34172AC9-069D-45BA-84C3-540A22DAFD18Q39098495-B6220EB7-5BF7-4C58-B76C-2AAF203DC332Q39919107-B6BE2094-15BF-4309-AA51-A026322D87A2Q42158814-A9C4A1C4-ADF6-4554-B17F-C5722ED5D168Q42335445-B1F76B57-4C37-4257-8050-AF1ABBFB997DQ46377527-5B4C7C5E-FD3B-4AFF-AE0E-90672E1EB369Q47126115-6151BCB0-1302-4E35-8878-977BB330BA3DQ47139391-0F683624-4F4C-4F8A-9B3B-CDC8CB54376FQ47192906-FBFCB1FD-F29F-401A-AB3B-0E2017E3A8FDQ47817767-81815F9A-DF56-46D2-A975-65D307DB3378
P2860
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@en
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@nl
type
label
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@en
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@nl
prefLabel
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@en
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@nl
P2093
P921
P1476
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
@en
P2093
Christian D Schubart
Iris E C Sommer
Rogier L Goetgebuer
Willemijn A van Gastel
P304
P356
10.1016/J.SCHRES.2011.04.017
P407
P577
2011-05-17T00:00:00Z